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Abstract
Purpose Metabolic syndrome in patients with morbid obesity causes a higher cardiovascular morbidity, eventually leading to left
ventricular hypertrophy and decreased left ventricular ejection fraction (LVEF). Roux-en-Y gastric bypass (RYGB) is considered
the gold standard modality for treatment of morbid obesity and might even lead to improved cardiac function. Our objective is to
investigate whether cardiac function in patients with morbid obesity improves after RYGB.
Materials and Methods In this single center pilot study, 15 patients with an uneventful cardiac history who underwent RYGB
were included fromMay 2015 to March 2016. Cardiac function was measured by cardiac magnetic resonance imaging (CMRI),
performed preoperatively and 3, 6, and 12 months postoperative. LVEF and myocardial mass and cardiac output were measured.
Results A total of 13 patients without decreased LVEF preoperative completed follow-up (mean age 37, 48.0 ± 8.8). There was a
significant decrease of cardiac output 12 months postoperative (8.3 ± 1.8 preoperative vs. 6.8 ± 1.8 after 12 months, P = 0.001).
Average myocardial mass declined by 15.2% (P < 0.001). After correction for body surface area (BSA), this appeared to be non-
significant (P = 0.36). There was a significant improvement of LVEF/BSA at 6 and 12 months postoperative (26.2 ± 4.1 preop-
erative vs. 28.4 ± 3.4 and 29.2 ± 3.6 respectively, both P = 0.002). Additionally, there was a significant improvement of stroke
volume/BSA 12 months after surgery (45.8 ± 8.0 vs. 51.9 ± 10.7, P = 0.033).
Conclusion RYGB in patients with morbid obesity with uneventful history of cardiac disease leads to improvement of cardiac
function.
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Background
Morbid obesity is characterized by multiple pathophysiologi-
cal processes leading to changes in metabolism and eventually
functional impairment [1]. One of the obesity-related comor-
bidities is cardiac morbidity, including left ventricular hyper-
trophy (LVH) as well as diminished left ventricular ejection
fraction (LVEF) [2]. Bariatric surgery is a well-established and
effective treatment for morbid obesity, including improvement
of obesity-related comorbidities such as hypertension, dyslip-
idemia, and type 2 diabetes mellitus [3]. Several studies have
been performed to analyze changes in cardiac function in pa-
tients with preoperative cardiomyopathy, showing improve-
ment in cardiac function after Roux-en-Y gastric bypass
(RYGB) [4–6]. As measured by cardiac ultrasound (CUS), it
has been stated that cardiac function may also benefit from
bariatric surgery in patients without cardiac history, eventually
resulting in improved left ventricular function (LVF) and di-
minished left ventriclemass (LVM) and diameter. This poten-
tially leads to a decrease of LVH and an increase of LVEF [4,
7–9]. The decrease in body mass index (BMI) after bariatric
surgery seems to be correlated with the decrease in LVM [2].
Cardiac magnetic resonance imaging (CMRI) is less seriously
influenced by subcutaneous fat than CUS, and can determine
functional parameters, such as dimensions of the left ventricle
(LV), LVM, and LVEF [7, 10–13]. Therefore, the gold stan-
dard for measurement of cardiac function in patients with
morbid obesity should be CMRI. Previous studies to assess
changes in cardiac function in patients without a history of
cardiac disease have been performed using CUS, and there-
fore we performed a pilot study to investigate whether cardiac
function in patients with morbid obesity with uneventful car-
diac history improves after RYGB as measured by CMRI
[14–16].
Methods
Study Population
A total of 15 patients who underwent RYGB at the Maasstad
Hospital in Rotterdam from September 2015 to May 2016
were included in this study. CMRI could not be performed
in two patients as they were claustrophobic. Therefore, the
data of these patients were excluded from this study.
Surgical Procedure
All procedures were performed by experienced bariatric sur-
geons. First, a gastric pouch of 25 cc was created. A 50-cm
biliopancreatic limb was measured and the gastrojejunostomy
was created using an endostapler and a continuous, absorbable
suture. A side-to-side jejunojejunostomy was created using an
endostapler and a continuous, absorbable suture, with an ali-
mentary limb of 150 cm. Afterward, a transection between
both anastomoses of the jejunum was performed.
Postoperative Care
Postoperative care was performed by our standard postopera-
tive care protocol. In this protocol, all patients were seen at the
outpatient clinic 2 weeks, 3, 6, 9, and 12 months postopera-
tive. All patients were counseled by a dietician, consisting of
two group sessions and four individual consultations in the
first year postoperative. All patients were advised to consume
a calorie-restricted, high-protein diet consisting of approxi-
mately 1000 cal per day and 60–80 g of protein per day. All
patients were advised to do moderate-intensity physical activ-
ities for at least 30 min per day. In addition, patients were
advised to exercise for 1 h at least twice a week.
Cardiac Magnetic Resonance Imaging
Imaging was performed with a 1.5 Tesla Siemens Somatom
Definition scanner (Siemens AG, Erlangen, Germany). Short
axis multislice cine TRUE FISP series of the heart were ob-
tained for LV function analysis. In addition, post contrast se-
ries using gadolinium contrast agent (Bayer AG, Leverkusen,
Germany) were obtained for the detection of late enhance-
ment, a parameter to objectify ischemic changes of the
myocardium.
CMRI Data Analysis
CMRI data analysis was performed using Siemens syngo.via
versions 10 and 11 (Siemens AG, Erlangen, Germany). By
drawing the endocardial and epicardial contours of the myo-
cardium, a 3Dmodel was obtained. Via this model, the LVEF,
end diastolic volume (EDV), end systolic volume (ESV),
stroke volume (SV), cardiac index (CI), myocardial mass
(MM; at end diastolic phase), peak ejection rate (PER), and
peak filling rate (PFR) were calculated.
In addition to functional CMRI studies, we obtained blood
samples to evaluate the effects of RYGB on the metabolic
syndrome in these patients, such as kidney function, liver
function, and lipid spectrum. We also determined leptin and
ghrelin and the cardiac NT-pro BNP and vWF antigen.
Statistical Analysis
Body surface area (BSA) was measured using the Du Bois
formula [17]:
BSA ¼ 0:007184Weight in kgð Þ0:425
 Height in cmð Þ0:725
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Statistical analysis was performed with IBM SPSS
Statistics, version 23 (SPSS, Chicago, IL). Continuous data
are presented as the mean ± standard deviation. Percentage
excess weight loss (%EWL) was measured with the ideal
weight defined by the weight corresponding to a BMI of
25 kg/m2. Analysis of repeatedmeasures was performed using
linear mixed models. A P value < 0.05 was considered signif-
icant. Missing data were addressed with pairwise deletion of
missing data.
Results
Clinical Characteristics
A total of 13 patients with a mean age of 48.0 ± 8.8 years were
included in this study, of whom 8 (61.5%) were female. There
was a significant increase of %EWL of 46.4%, 67.8%, and
84.5% % at 3, 6, and 12 months after surgery respectively
(P < 0.001). As a result, BSA decreased significantly after 3,
6, and 12 months, from 2.3 m2 preoperative to 2.0 m2 after
12 months. Heart rate and systolic blood pressure decreased
significantly after 6 and 12 months (P < 0.001) (Table 1).
Changes in Cardiac Function
Cardiac output declined significantly 12 months after bariatric
surgery (8.3 ± 1.8 vs. 6.8 ± 1.8, P = 0.001). Heart rate declined
significantly at 6 and 12months after bariatric surgery (67.5 ±
9.5 and 66.3 ± 12.2, P < 0.05). The average MM declined by
15.2% (P < 0.001) (Table 2). However, after correction for
changes in BSA, no significant decline was seen 12 months
postoperative (P = 0.36). LVEF declined significantly only at
3 months postoperative (56.6 ± 6.6, P < 0.05). However, after
correction for BSA, there was a significant increase in LVEF/
BSA ratio 6 and 12 months postoperative (both, P = 0.002)
(Fig. 1). SV did nog change significantly. Additionally, there
was a significant increase in SV/BSA ratio after 12 months
follow-up (45.8 ± 8.0 versus 51.9 ± 10.7, P = 0.033). These
results did not change after exclusion of one female patient
in whom a right bundle branch block was found by coinci-
dence. No patients had delayed myocardial enhancement.
Detected by CMRI, all patients had hepatic steatosis preoper-
ative, which completely disappeared 3 to 6 months postoper-
ative in all study subjects.
Correlation of Blood Test Results and Cardiac
Function
Even though there is a significant decrease of LDL and tri-
glycerides and significant increase of HDL at 12 months after
surgery (Table 3), there was no correlation between the im-
provement of the lipid spectrum and the increase of the LVEF/
BSA ratio (P = 0.105, P = 0.127, P = 0.197, and P = 0.767
respectively). Additionally, the significant decrease of leptin
levels does not seem to influence the LVEF/BSA ratio (P =
0.072).
Discussion
This is the first CMRI study to assess cardiac changes after
RYGB performed in patients with an uneventful cardiac his-
tory. We found a significant increase in LVEF, even after cor-
rection for BSA (LVEF/BSA) after RYGB. Additionally, we
found a significant decrease in non-corrected cardiac output
and absolute LV mass 12 months postoperatively. SV/BSA
significantly improved after 12 months and none of the pa-
tients showed signs of myocardial ischemia. Due to the nec-
essary increase of cardiac output, needed for enhanced blood
supply to the excess peripheral tissue, obesity is associated
with a chronic higher cardiac workload as compared to
Table 1 Clinical characteristics
Variable Preoperative Postoperative (months)
3 6 12
Pulse (/min) 83.8 ± 16.2 72.3 ± 12.8 67.5 ± 9.5* 66.3 ± 12.2*
Systolic BP 143.3 ± 22.6 126.3 ± 10.5* 127.2 ± 11.9* 133.1 ± 22.7*
Diastolic BP 86.6 ± 14.3 87.9 ± 13.2 88.9 ± 10.1 89.4 ± 14.8
BMI (kg/m2) 40.1 ± 2.1 33.2 ± 2.6* 30.0 ± 2.7* 27.5 ± 3.8*
BSA 2.3 ± 0.2 2.1 ± 0.2* 2.1 ± 0.1* 2.0 ± 0.2*
%TWL 17.0 ± 4.2 25.1 ± 5.5† 31.2 ± 8.1
%EWL 46.4 ± 14.0 67.8 ± 17.2† 84.5 ± 23.2†
BP, blood pressure; BMI, body mass index; BSA, body surface area;%TWL, percentage total weight loss;%EWL,
percentage excess weight loss
*Significant (P < 0.05) versus preoperatively
†Significant as compared to %TWL or %EWL after 3 months using the paired Student’s T test
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healthy individuals. This will eventually lead to LVH as de-
scribed by multiple studies [2, 18, 19]. One of these studies
was obtained in a group of patients with a BMI > 50, in con-
trast to our test group with a median BMI of 40.1 preopera-
tively [20]. As the blood supply to the peripheral tissue de-
creases after significant weight loss, it is expected that the
cardiac workload will change, and therefore the cardiac func-
tion will improve after bariatric surgery. In our study, there
was no significant change in non-BSA-corrected LVEF after
bariatric surgery. Two other studies have found comparable
results [21, 22]. It could be possible that in the presence of
depressed wall mechanics, ejection fraction is sustained by
increased concentricity of LV geometry. A simultaneous re-
duction of concentricity with improvement in mid wall me-
chanics is expected to leave ejection fraction unchanged.
Nevertheless, due to the significant decrease in BSA, a
Table 2 Cardiac function based
on magnetic resonance imaging Variable Preoperative Postoperative (months)
3 6 12
MRI
LVEF (%) 60.2 ± 6.9 56.6 ± 6.6* 58.3 ± 6.1 58.0 ± 6.3
ED volume (ml) 177.6 ± 35.0 176.8 ± 44.9 183.5 ± 46.3 180.1 ± 43.6
ES volume (ml) 71.3 ± 20.1 77.2 ± 24.0 76.8 ± 22.5 71.3 ± 20.1
Stroke volume (ml) 106.3 ± 22.2 99.5 ± 25.9 106.7 ± 28.1 104.8 ± 29.7
Cardiac output (l/min) 8.3 ± 1.8 6.7 ± 1.3* 6.6 ± 1.4* 6.8 ± 1.8*
Myocardial mass (ED, in g) 127.4 ± 35.5 113.2 ± 33.3* 111.7 ± 31.1* 111.8 ± 34.0*
Myocardial mass (Average, in g) 140.6 ± 35.7 121.2 ± 34.3* 115.8 ± 30.6* 119.2 ± 36.0*
Peak ejection rate (ml/s) − 505.7 ± 135.3 − 479.5 ± 93.7 − 471.0 ± 92.6 − 471.3 ±
116.2*
Peak ejection time (ms) 113.5 ± 20.8 125.3 ± 34.9 131.9 ± 26.0* 146.6 ± 28.3*
Peak filling rate (ml/s) 501.5 ± 78.8 447.0 ± 116.6 438.3 ± 143.7* 443.8 ± 113.5*
Peak filling time (ms) 546.5 ± 101.5 660.4 ± 198.9 527.0 ± 209.2 622.0 ± 180.1
MRI/BSA
LVEF/BSA (%/m2) 26.2 ± 4.1 27.0 ± 4.4 28.4 ± 3.4* 29.2 ± 3.6*
ED volume/BSA (ml/m2) 76.5 ± 12.0 83.0 ± 16.5* 88.4 ± 18.0* 89.3 ± 15.2*
ES volume/BSA (ml/m2) 30.7 ± 8.0 36.1 ± 9.1* 37.1 ± 9.6* 37.4 ± 7.6*
Stroke volume/BSA (ml/m2) 45.8 ± 8.0 46.9 ± 10.5 51.4 ± 11.1* 51.9 ± 10.7*
Cardiac index (ml/min/m2) 3.6 ± 0.6 3.1 ± 0.5* 3.2 ± 0.6* 3.4 ± 0.7
Myocardial mass/BSA (ED, in
g/m2)
54.4 ± 11.1 52.9 ± 12.1 53.7 ± 12.0 55.3 ± 13.5
Myocardial mass/BSA
(Average, in g/m2)
60.1 ± 10.6 56.7 ± 12.2* 55.7 ± 11.4* 58.7 ± 13.5
Peak ejection rate/BSA (ml/s/-
m2)
− 216.4 ± 43.1 − 226.0 ± 36.1 − 227.5 ± 35.6 −233.7 ± 40.8*
Peak filling rate/BSA (ml/s/m2) 216.7 ± 26.9 211.6 ± 54.6 211.3 ± 65.1 220.2 ± 41.9
Additional findings
Late enhancement (n) 0 0 0 0
Hepatic steatosis 13 2 0 0
MRI, magnetic resonance imaging; LVEF, left ventricular ejection fraction; ED, end diastolic; ES, end systolic;
BSA, body surface area
*Significant (P < 0.05) versus preoperative
Fig. 1 Changes in left ventricular ejection fraction / body surface area
ratio. LVEF, left ventricular ejection fraction; BSA, body surface area
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significant change in LVEF/BSA was seen after 6 and
12 months, despite the small study population. In line with
this, there was a significant increase in SV/BSA ratio after
12 months of follow-up. Furthermore, a significant decrease
in heart rate and systolic blood pressure was found as a result
of loss of volume, and thus a decrease of cardiac afterload.
Eventually, there was a significant decrease in cardiac output
12 months postoperatively.
After 3 months, some patients showed a (slight) decrease in
EDVand SV. Theoretically, this might be due to lipolysis and/
or the cardiodepressive effect of released free fatty acids
(FFA) and its associated cardiotoxicity. However, in our pop-
ulation, there was a decrease in serum triglycerides [23]. An
explanation for this could be the release of lipid droplets (LDs)
which can become cardiotoxic [24].
Besides these theories, it is conceivable that in the first
3 months postoperative, there is a derangement of a stable
but adipose state to a katabolic state, which alone has a
cardiodepressive effect [25]. The temporary increase in FFA
after surgery (due to lipolysis by the acute weight loss) could
have a cardiotoxic effect on heart function, just like diabetic
cardiomyopathy [26]. Furthermore, there are multiple me-
chanical changes in cardiac function load and LVF in patients
with morbid obesity, for example, increased RV load and
OSAS. Because the relative onset of all these cardiac changes
is due to the biggest weight loss, the emphasis is on BSA-
corrected values. When BSA-corrected values are used, there
is an overall improvement as seen in other studies [27].
We detected a 15.2% reduction of LV mass in our patients,
which is comparable to other studies measured by CUS [18,
19, 21, 28]. These studies reported mass reductions of 16–
22%. However, after correction for changes in BSA, no sig-
nificant decline was found 12 months postoperatively. There
is no evidence that the degree of increase in LVEF and de-
crease in LV mass is determined by the type of bariatric sur-
gical procedure [29].
In all patients, a significant decrease of BMI (up to 31%)
and BSA was found as compared to the preoperative
condition, which is to be expected after RYGB. In our study,
we have corrected the cardiac function outcomes for BSA as
heart function is correlated with BSA and without correction
the LVEF would change dramatically. Correction for BSA
using the DuBois formula is known for an underestimation
of the BSA in patients with obesity of 3% in male patients
and 5% in female patients [30]. BSA is generally accepted and
widely used to assess cardiac function [31]. The most accurate
correction, however, would be with the measurement of the
patient’s volume using a 3-dimensional body scanner [32].
Unfortunately, this technique was not available at our hospital
during our study.
In a larger study with 312 patients with higher BMI’s,
Brownell et al. reported that the presence of LVH was inde-
pendently associated with BMI ≥ 50 and female sex, after
adjusting for age, diabetes, hypertension, and pulmonary hy-
pertension [20]. As there was no significant LVH preopera-
tively in our group, we cannot confirm this. A possible expla-
nation for the differences in LVH between these test groups
and our test group could be the lower BMI in our test group. In
one study (n = 10), adenosine-induced sub-endocardial ische-
mia was reported at baseline [9]. Half of the patients in this
study underwent bariatric surgery, resulting in complete nor-
malization of ischemia in 3 out of 5 patients and partial im-
provement in the remaining 2 patients. As determined by
CMRI, none of the patients in our study had signs of previous
infarction. For logistic reasons, we could not use adenosine
CMRI for detection of reversible stress-induced myocardial
ischemia.
Hepatic steatosis is closely linked to obesity. This linkage is
based on the fact that obesity results in marked enlargement of
the intra-abdominal visceral fat depots. The eventual develop-
ment of insulin resistance leads to continuous lipolysis within
these depots, releasing fatty acids into the portal circulation,
where they are rapidly translocated to the liver and
reassembled into triglycerides [33]. All of our 13 patients
had hepatic steatosis preoperatively. This disappeared in 11
patients 3 months after the bariatric procedure. In the other 2
Table 3 Blood test results
Variable Preoperative Postoperative (months)
3 6 12
Lipid spectrum
Cholesterol 5.2 ± 1.2 4.6 ± 1.1* 4.7 ± 0.9 4.7 ± 0.9
HDL 1.2 ± 0.3 1.2 ± 0.4 1.3 ± 0.4 1.4 ± 0.5*
LDL 3.2 ± 0.8 2.6 ± 1.0* 2.6 ± 0.9* 2.5 ± 0.8*
Triglycerides 2.6 ± 1.4 1.7 ± 0.7* 1.8 ± 1.0* 1.8 ± 1.4*
Metabolic biomarkers
Leptin 90.6 ± 44.5 33.9 ± 22.0* 26.6 ± 15.0* 18.9 ± 7.7*
Ghrelin 650.5 ± 146.1 691.7 ± 124.3 725.4 ± 260.2 675.6 ± 165.8
*Significant (P < 0.05) versus preoperative
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patients, hepatic steatosis decreased significantly and disap-
peared after 6 months. This all is a direct consequence of
diminished intra-abdominal visceral fat depots after RYGB.
There was a significant decrease of LDL and triglyceride
levels and increase of HDL 12 months after RYGB. An im-
proved lipid spectrum after RYGB is associated with an im-
provement of the cardiovascular risk profile [34–36].
However, in our study, no correlation was found between
the improvement of the cardiac function and the improvement
of the lipid spectrum, which has also been shown in a study in
patients with preoperative heart failure [37]. Although cardio-
vascular risks decline due to an improved lipid spectrum, it
does not seem to be related to the improvement of cardiac
function. Priester et al. reported that weight loss achieved
through bariatric surgery is associated with less coronary cal-
cification and this effect, which appears to be independent of
changes in LDL-C, may contribute to lower cardiac mortality
in patients with successful gastric bypass [38]. Additionally,
Jonker et al. demonstrated that bariatric surgery results in a
significant decrease in carotid intima-media thickness in all
evaluated age categories, resulting in an improvement of car-
diovascular risks [39].
Glucose, leptin, and ghrelin levels could not consequently
be measured after fasting due to logistic limitations in CMRI
planning (mostly at the end of the day) and patient comorbid-
ity like diabetes.
Therefore, the results of glucose, leptin, and ghrelin out-
comes could not be used for analysis. Our study is limited by
the small study population. We started with 15 patients, but 2
patients had ustrophobia, even though they had a test visit to
the MRI before the study started. The MRI protocol of 45 min
was well-tolerated by the other 13 non-claustrophobic pa-
tients. Almost all patients stated the breath-holding technique
was easier to perform after weight loss. The quality of the
CMRI was good and there were no distractions due to the
subcutaneous fat. Therefore, we conclude that CMRI is a good
technique to assess cardiac function in the population with
morbid obesity. Further research in a larger study population
is recommended in order to have a better insight of the corre-
lations of different factors in relation to the improvement of
cardiac function. It is also recommended to obtain a 3D
whole-body scan to measure the whole-body volume for cor-
rection of the cardiac function instead of the BSA. In conclu-
sion, this study shows that CMRI is an effective imaging tech-
nique to objectively analyze cardiac functional changes in
patients with morbid obesity. Also, an improvement of cardiac
function after RYGB is seen in patients with morbid obesity
without a history of cardiac disease.
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